3 Biotechs Beating the Market

On a day when the Dow Jones Industrial Average (INDEX: ^DJI) fell 190 points on thin trading as high gas prices combined with the European debt drama, significantly larger moves happened in the health-care sector. For instance, Geron (NAS: GERN) which shocked investors yesterday after announcing the elimination of its stem-cell program, added another 7% to its continuing slide today.

But instead, let's focus on what went right. We have a duo of biotechs that had a great showing, along with a medical-device maker popping after hours.

Investors in little-known ARCA Biopharma are 43% richer than they were when they woke up, all thanks to a positive trial result. The company's drug candidate, GencaroTM, is hoping to carve out space in the large and lucrative atrial fibrillation market. It had a 74% reduction in new a-fib onsets for patients with a relatively common genotype.

Don't feel bad if you've never heard of ARCA. Even after its rocket shot, the company's market cap is below $20 million. Considering a-fib treatments are where heavyweights like Bristol-Myers Squibb (NYS: BMY) and Johnson & Johnson play, ARCA has an uphill battle in front of it.

Meanwhile, BioSante Pharmaceuticals (NAS: BPAX) jumped 8% after the company revealed that its female sexual dysfunction product LibiGel improved free testosterone levels in women post-menopause. The real winner, though, may be Antares Pharma (ASE: AIS) , whose gel BioSante uses to deliver the drugs to patients. Not only does Antares have a huge financial stake in LibiGel's success, but it also further validates its platform, which is also licensed out to Jazz Pharmaceuticals (NAS: JAZZ) . LibiGel is currently in phase 3 trials that the FDA signed off on, so as long as the efficacy and safety profile are solid, investors are looking at a less surprise-filled approval process.

Finaly, Zoll Medical (NAS: ZOLL) reported estimate-beating fourth-quarter results after the market closed. Thanks to a 57% sales increase of its LifeVest defibrillator, Zoll managed earnings growth of 65%. More exciting yet are the company's 2012 estimates. At the high end, management believes 19% revenue growth is achievable, or a full $20 million more than the $603 million analysts had expected. The good news erased a 5% decline that happened during the trading session, and if management's assessments are accurate, more good days lay ahead for investors.

For a handy way to keep track of the companies mentioned here, add them to our free My Watchlist feature:

At the time this article was published David Williamsonowns shares of Johnson & Johnson, but he holds no other position in any company mentioned. Check out hisholdings and a short bio. The Motley Fool owns shares of Johnson & Johnson.Motley Fool newsletter serviceshave recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.